Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Public ClinicalTrials.gov record NCT01088763. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study identification
- NCT ID
- NCT01088763
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 129 participants
Conditions and interventions
Conditions
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- Childhood Central Nervous System Mixed Germ Cell Tumor
- Childhood Central Nervous System Teratoma
- Childhood Central Nervous System Yolk Sac Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Ependymoblastoma
- Childhood Grade I Meningioma
- Childhood Grade II Meningioma
- Childhood Grade III Meningioma
- Childhood Infratentorial Ependymoma
- Childhood Medulloepithelioma
- Childhood Mixed Glioma
- Childhood Oligodendroglioma
- Childhood Supratentorial Ependymoma
- Gonadotroph Adenoma
- Pituitary Basophilic Adenoma
- Pituitary Chromophobe Adenoma
- Pituitary Eosinophilic Adenoma
- Prolactin Secreting Adenoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Central Nervous System Embryonal Tumor
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Childhood Spinal Cord Neoplasm
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Childhood Visual Pathway Glioma
- Recurrent Pituitary Tumor
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- T-cell Childhood Acute Lymphoblastic Leukemia
- T-cell Large Granular Lymphocyte Leukemia
- TSH Secreting Adenoma
- Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
- gamma-secretase/Notch signalling pathway inhibitor RO4929097 Drug
- diagnostic laboratory biomarker analysis Other
- pharmacological study Other
- dexamethasone Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2010 (Type not available)
- Primary completion
- May 2011 (Actual)
- Completion
- May 2011 (Actual)
- Last update posted
- Nov 5, 2014
2010 – 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Lucile Packard Children's Hospital Stanford University | Palo Alto | California | 94304 | — |
| Stanford University Hospitals and Clinics | Stanford | California | 94305 | — |
| Lurie Children's Hospital-Chicago | Chicago | Illinois | 60614 | — |
| Indiana University Medical Center | Indianapolis | Indiana | 46202 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Nationwide Children's Hospital | Columbus | Ohio | 43205 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01088763, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2014 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01088763 live on ClinicalTrials.gov.